"Temporal lobe necrosis" from_date:2012

Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer. Temporal lobe necrosis (TLN) is a potential late effect after radiotherapy for skull base head and neck cancer (HNC). Several photon-derived dose constraints and normal tissue complication probability (NTCP) models have been proposed, however

Tumor-infiltrating T-cell Receptor-beta Repertoires are Linked to the Risk of Late Chemoradiation-induced Temporal Lobe Necrosis in Locally Advanced Nasopharyngeal Carcinoma. Temporal lobe necrosis (TLN), a late complication of nasopharyngeal carcinoma (NPC) after concurrent chemoradiotherapy (CCRT), causes permanent neurologic deficits. We aimed to investigate the risk factors

Asymptomatic Evolution and Regression of Temporal Lobe Necrosis After Adjuvant Radiation for Skin Cancer: A Case Report and Review of Literature Temporal Lobe Necrosis (TLN) is not an expected complication of adjuvant radiation therapy (RT) for skin cancers and has become uncommon otherwise in daily practice due to improved RT planning and modern delivery techniques. TLN is a great mimic and can

Comparison of radiological and clinical features of temporal lobe necrosis in nasopharyngeal carcinoma patients treated with 2D radiotherapy or intensity-modulated radiotherapy To compare the imaging and clinical features of temporal lobe necrosis (TLN) in nasopharyngeal carcinoma (NPC) patients treated with two-dimensional radiotherapy (2D-RT) or those with intensity-modulated radiotherapy

A Study of Radiation-Induced Cerebral Vascular Injury in Nasopharyngeal Carcinoma Patients with Radiation-Induced Temporal Lobe Necrosis To investigate radiation-induced carotid and cerebral vascular injury and its relationship with radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma (NPC) patients. Fifty eight NPC patients with radiation-induced temporal lobe necrosis (TLN patients who were free from radiation-induced temporal lobe necrosis after radiotherapy and 29 healthy individuals. Significant differences in IMT, occurrence of plaques of ICAs and flow velocities of both MCAs and ICAs were found between patients after radiotherapy and healthy individuals (p<0.05). IMT had positive correlation with post radiation interval (p = 0.049). Compared with results from patients

in the standard fractionation group (16 [24%], including two [3%] nasopharyngeal necrosis, 11 [16%] nasal haemorrhage, and three [4%] temporal lobe necrosis). Hyperfractionated intensity-modulated radiotherapy could significantly decrease the rate of severe late complications and improve overall survival among patients with locally advanced recurrent nasopharyngeal carcinoma. Our findings suggest

lobe necrosis (TLN). It is currently believed that the mechanism of radiation-induced TLI involves microvascular injury, neuron and neural stem cell injury, glial cell damage, inflammation, and the production of free radicals. Significant RT-related structural changes and dose-dependent changes in gray matter (GM) and white matter (WM) volume and morphology were observed through computed tomography Research progress on mechanism and imaging of temporal lobe injury induced by radiotherapy for head and neck cancer. Radiotherapy (RT) is an effective treatment for head and neck cancer (HNC). Radiation-induced temporal lobe injury (TLI) is a serious complication of RT. Late symptoms of radiation-induced TLI are irreversible and manifest as memory loss, cognitive impairment, and even temporal

sarcoma [1] HSV-1 is a common cause of infectious encephalitis; it causes necrotizing hemorrhagic encephalitis, typically involving the temporal lobes. Herpes simplex encephalitis is characterized by acute onset of symptoms, including fever, headache, altered mental status, seizures, and focal neurologic deficits resulting from frontal and temporal lobe necrosis. If left

of complications with 2-D techniques [5,7,21-24]. These complications included visual complications (chronic pain and visual loss), pituitary dysfunction, osteoradionecrosis, and frontal/temporal lobe necrosis. The development of 3-D techniques and intensity-modulated RT (IMRT) has led to a decline in the rate of these complications. Chen et al [25] reviewed their single-institutional experience %, respectively. One patient developed grade 3 radiation-induced visual impairment. Temporal lobe necrosis was noted in 3 patients on long-term follow-up. The use of proton therapy has also been reported for unresectable nasal cavity and paranasal sinus cancers. Locally advanced sphenoid sinus cancers of various histologies were treated to a dose of 76 Gy equivalent (GyE) [27

%, respectively. Multivariable analysis revealed that older age (P = .017) was predictive of worse OS, whereas a larger tumor volume (P = .049) and a lower biological equivalent dose (P = .029) were associated with inferior local control. No patient developed an acute toxicity of ≥grade 3 during CIRT. Severe (≥grade 3) late toxicities included temporal lobe necrosis (0.97%), cranial neuropathy (0.49%), hearing

-year local recurrence-free survival, regional recurrence-free survival, distant metastasis-free survival, and overall survival were 90.3%, 88.3%, 90.3%, and 91.2%, respectively. Among late IMRT-related adverse events, we recorded 2 patients with G1 cranial nerve injury, 3 patients with G3 hearing loss, and 3 patients with G3 subcutaneous fibrosis. No patients had temporal lobe necrosis, brain stem

, 0.30; 95% CI, 0.11-0.80;  = .02); for FFS in the stage II subgroup (HR, 0.42; 95% CI, 0.24-0.73;  = .002); and for OS in the stage I (HR, 0.20; 95% CI, 0.04-0.96;  = .04), stage II (HR, 0.39; 95% CI, 0.21-0.75;  = .004), and stage IVA-B (HR, 0.74, 95% CI, 0.56-0.98;  = .04) subgroups. The incidence of grade 3-4 temporal lobe necrosis, cranial neuropathy, eye damage, ear damage, neck soft tissue

Implementation of temporal lobe contouring protocol in head and neck cancer radiotherapy planning: A quality improvement project. Temporal lobe necrosis as result of radiation for nasopharyngeal cancer (NPC) occurs up to 28% of NPC patients. The only effective mitigation is by strict adherence to temporal lobe dose tolerances during radiotherapy planning, which in turn hinges on accurate temporal

3 or 4) toxicities were infrequent, but included mucosal necrosis (9.3%), xerostomia (1.3%), and temporal lobe necrosis (1.3%). This initial experience in the first 75 patients with locoregionally recurrent NPC was encouraging. Carbon ion RT could provide promising survival rates with infrequent severe toxicities for patients with locoregionally recurrent NPC. Cancer 2018;124:2427-37. © 2018

response rate was 30.8%, and the locoregional control rate at 3 years was 49.2%. Temporal lobe necrosis (TLN) developed in 8 cases. The rates of grade ≥3 hearing loss, soft tissue necrosis, dysphagia, and trismus were 30.8%, 15.4%, 11.5%, and 19.2%, respectively. Overall, 5 patients died owing to acute (1 after cycle 1 TPF and 1 after completion of bio-chemoradiotherapy) or late (2 epistaxis and 1 TLN

common acute toxicity was mucositis; 124 (27.2%) patients experienced grade 3-4 mucositis; 46 (10.1%) experienced serious late toxicities. The most common late toxicity was MRI-detected radiation-induced temporal lobe necrosis (6.8%). The RTOG IMRT protocols are feasible for patients with NPC from the endemic regions of China.

). A multivariate analysis demonstrated the prognostic value of tumor response to IC for LFFS. Dosimetric analysis showed good homogeneity, and the dose constraints were stringent. Asymptomatic temporal lobe necrosis in the ipsilateral side of tumor occurred in one patient. IMRT using a reduced GTV delineation delivered satisfactory doses to the target volumes and avoided overdosing of critical neurological

by neurological organs remained well within their dose constraints. No patients developed temporal lobe necrosis or other neurological dysfunctions. With relative underdosed IMRT plus effective chemotherapy, the patients achieved satisfactory local control with few late toxicities of the central nervous system. Determining the acceptable extent of dosimetric inadequacy requires further exploration.

survival rates were 60.9%, 78.3% and 27.5%, respectively. The presence of severe late complications, recurrent T4 disease and gross tumor volume >30 cm3 were associated with poor survival. The incidences of mucosal necrosis, temporal lobe necrosis, cranial neuropathy and trismus were 22.0%, 14.6%, 27.0% and 14.6% respectively. Re-irradiation with IMRT is an effective choice in patients with locally